Ovid Therapeutics Inc.
OVID
$0.2959
-$0.0065-2.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.61% | 44.39% | 113.30% | 186.29% | 284.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.61% | 44.39% | 113.30% | 186.29% | 284.12% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 15.61% | 44.39% | 113.30% | 186.29% | 284.12% |
| SG&A Expenses | -10.09% | -9.77% | -15.31% | -13.48% | -13.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.07% | 6.80% | 24.81% | 20.91% | 8.33% |
| Operating Income | 6.24% | -6.54% | -24.32% | -20.30% | -7.71% |
| Income Before Tax | 50.72% | 49.50% | 33.02% | 39.58% | 1.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 50.72% | 49.50% | 33.02% | 39.58% | 1.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 50.72% | 49.50% | 33.02% | 39.58% | 1.44% |
| EBIT | 6.24% | -6.54% | -24.32% | -20.30% | -7.71% |
| EBITDA | 6.41% | -6.53% | -24.64% | -20.64% | -7.84% |
| EPS Basic | 51.06% | 49.41% | 34.80% | 41.23% | 3.48% |
| Normalized Basic EPS | 53.65% | 44.14% | 28.32% | 34.87% | -2.66% |
| EPS Diluted | 50.99% | 49.40% | 34.23% | 40.85% | 2.63% |
| Normalized Diluted EPS | 53.57% | 44.06% | 28.23% | 34.78% | -2.66% |
| Average Basic Shares Outstanding | 0.49% | 0.46% | 0.42% | 0.36% | 0.27% |
| Average Diluted Shares Outstanding | 0.59% | 0.56% | 0.52% | 0.46% | 0.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |